Identified mitochondrial oxidative stress as central hub in diabetic retinopathy, supporting metabolic interventions for fundamental pathophysiology.
Our findings further support the use of 670 nm light as an effective treatment against retinal degeneration as well as shedding light on the mechanism of protection through the increase of the mitochondrial spare respiratory capacity.
670 nm increased RPE phagocytic activity 25-40% through enhanced ATP and receptor expression, addressing critical waste clearance function in AMD.
Near-infrared light restored mitochondrial ATP production, demonstrating PBM can compensate for genetic AMD risk factors.
LLLT stabilized visual fields and improved subjective visual function in retinitis pigmentosa patients without adverse effects, expanding clinical evidence.
Near-infrared 670 nm light significantly increased ATP production in aging retinal tissue, providing quantitative evidence for mitochondrial recharging.
Conclusions: PBM potentially offers a non-invasive and cost-effective therapeutic option for patients with NCDME. Further studies of this therapeutic option in DR are warranted.
After four initial treatments of LLLT, visual acuity increased to 20/20 in each eye. Visual fields normalized except for a mid-peripheral absolute concentric scotoma. Five years after discontinuation of LLLT, a relapse was observed. LLLT was repeated (another four treatments) and restored the initial success.
This case report describes the effects of low-level laser therapy (LLLT) in retinitis pigmentosa (RP). 670 nm LED superior to 830 nm for retinal/optic nerve protection, reducing reactive oxygen species and oxidative DNA damage.
670 nm preserved 40% more retinal ganglion cells following optic nerve crush injury through enhanced mitochondrial function and reduced oxidative stress.
